Metropolis Healthcare Limited
METROPOLIS · Hospitals · NSE
₹473
Current Market Price
Fair Value (DCF)
₹282
Margin of Safety
-40.3%
Updated 2d ago
YieldIQ Score
43/100
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
39%
ROE
10.9%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹9,808 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
—
Return on capital employed
EV / EBITDA
29.4×
Enterprise multiple
Debt / EBITDA
0.6×
Leverage vs earnings
Interest Coverage
11.3×
EBIT covers interest
Current Ratio
—
Short-term liquidity
Asset Turnover
0.78×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
7.9%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹473.05
Bear case
₹168.98
MoS -179.9%
Base case
₹282.42
MoS -67.5%
Bull case
₹380.81
MoS -24.2%
Ratio Trends
METROPOLIS · last 7 annual periods
ROE
10.9%
ROCE
20.7%
Operating Margin
—
Debt / Equity
0.15×
PE
648.2×
EV / EBITDA
85.4×
Historical Financials
METROPOLIS · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹998 Cr | ₹261 Cr | ₹264 Cr | ₹331 Cr | ₹1331 Cr | +7.5% |
| EBITDA | — | ₹376 Cr | ₹304 Cr | ₹292 Cr | ₹318 Cr | -4.1% |
| EBIT | ₹252 Cr | ₹52.2 Cr | ₹54.6 Cr | ₹56.1 Cr | — | -31.3% |
| PAT | ₹183 Cr | ₹33.1 Cr | ₹39.9 Cr | ₹36.5 Cr | ₹145 Cr | -5.7% |
| EPS (diluted) | ₹35.79 | ₹6.43 | ₹7.78 | ₹7.08 | — | -33.3% |
| CFO | ₹249 Cr | ₹237 Cr | ₹238 Cr | ₹264 Cr | ₹263 Cr | +1.3% |
| CapEx | — | — | — | — | ₹-68.6 Cr | — |
| FCF | — | — | — | — | ₹194 Cr | +0.0% |
| Total Assets | — | ₹1345 Cr | ₹1434 Cr | ₹1555 Cr | ₹1867 Cr | +8.6% |
| Total Debt | — | ₹99.9 Cr | ₹51.5 Cr | ₹0.0 Cr | ₹204 Cr | +19.6% |
| Shareholders' Equity | — | ₹824 Cr | ₹936 Cr | ₹1096 Cr | ₹1335 Cr | +12.8% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
METROPOLIS vs 3 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| VIJAYA VIJAYA | — | — | Pending | 17.9% | — |
| THYROCARE THYROCARE | — | — | Pending | 16.7% | — |
| SYNGENE SYNGENE | — | — | Pending | 10.5% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for METROPOLIS in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of METROPOLIS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for METROPOLIS →
Compare
Head-to-head with peers
Compare METROPOLIS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse METROPOLISNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.